D
27.59
0.17 (0.62%)
| Previous Close | 27.42 |
| Open | 27.51 |
| Volume | 514,689 |
| Avg. Volume (3M) | 929,455 |
| Market Cap | 3,949,922,048 |
| Price / Sales | 3.64 |
| Price / Book | 2.27 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2024 - 11 Nov 2024 |
| Diluted EPS (TTM) | -2.76 |
| Total Debt/Equity (MRQ) | 3.99% |
| Current Ratio (MRQ) | 9.98 |
| Operating Cash Flow (TTM) | -362.64 M |
| Levered Free Cash Flow (TTM) | -212.81 M |
| Return on Assets (TTM) | -23.81% |
| Return on Equity (TTM) | -35.09% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Denali Therapeutics Inc. | Bearish | Bearish |
AIStockmoo Score
-0.9
| Analyst Consensus | -0.5 |
| Insider Activity | -1.0 |
| Price Volatility | -1.5 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -2.5 |
| Average | -0.90 |
|
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.66% |
| % Held by Institutions | 91.43% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 87.00 (HC Wainwright & Co., 215.33%) | Buy |
| Median | 37.00 (34.11%) | |
| Low | 24.00 (JP Morgan, -13.01%) | Buy |
| Average | 44.80 (62.38%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 22.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 07 Jan 2025 | 31.00 (12.36%) | Buy | 21.18 |
| HC Wainwright & Co. | 07 Jan 2025 | 87.00 (215.33%) | Buy | 21.18 |
| 07 Nov 2024 | 90.00 (226.21%) | Buy | 29.60 | |
| JP Morgan | 07 Jan 2025 | 24.00 (-13.01%) | Buy | 21.18 |
| Stifel | 16 Dec 2024 | 37.00 (34.11%) | Buy | 23.29 |
| Jefferies | 01 Nov 2024 | 45.00 (63.10%) | Buy | 27.05 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| HO CAROLE | 21.26 | 20.50 | 39,018 | 847,402 |
| KROGNES STEVE E. | - | 20.78 | -33,339 | -682,120 |
| SATO VICKI L | - | 20.84 | -3,080 | -64,187 |
| SCHUTH ALEXANDER O. | 21.26 | 20.50 | 39,018 | 847,402 |
| WATTS RYAN J. | 21.26 | 20.50 | 17,264 | 409,788 |
| Aggregate Net Quantity | 58,881 | |||
| Aggregate Net Value ($) | 1,358,285 | |||
| Aggregate Avg. Buy ($) | 21.26 | |||
| Aggregate Avg. Sell ($) | 20.60 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| KROGNES STEVE E. | Director | 07 Jan 2025 | Sell (-) | 3,339 | 21.18 | 70,720 |
| WATTS RYAN J. | Officer | 07 Jan 2025 | Sell (-) | 7,650 | 21.18 | 162,027 |
| SCHUTH ALEXANDER O. | Officer | 07 Jan 2025 | Sell (-) | 2,907 | 21.18 | 61,570 |
| HO CAROLE | Officer | 07 Jan 2025 | Sell (-) | 2,907 | 21.18 | 61,570 |
| WATTS RYAN J. | Officer | 06 Jan 2025 | Sell (-) | 29,266 | 19.82 | 580,052 |
| SCHUTH ALEXANDER O. | Officer | 06 Jan 2025 | Sell (-) | 12,255 | 19.82 | 242,894 |
| HO CAROLE | Officer | 06 Jan 2025 | Sell (-) | 12,255 | 19.82 | 242,894 |
| HO CAROLE | Officer | 03 Jan 2025 | Acquired (+) | 54,180 | 21.26 | 1,151,867 |
| SCHUTH ALEXANDER O. | Officer | 03 Jan 2025 | Acquired (+) | 54,180 | 21.26 | 1,151,867 |
| WATTS RYAN J. | Officer | 03 Jan 2025 | Acquired (+) | 54,180 | 21.26 | 1,151,867 |
| SATO VICKI L | Director | 02 Jan 2025 | Automatic sell (-) | 3,080 | 20.84 | 64,187 |
| KROGNES STEVE E. | Director | 31 Dec 2024 | Automatic sell (-) | 30,000 | 20.38 | 611,400 |
| Show more | ||||||
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |